A detailed history of Sherbrooke Park Advisers LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 2,004 shares of REGN stock, worth $1.39 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
2,004
Holding current value
$1.39 Million
% of portfolio
0.46%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$701.85 - $1046.91 $1.41 Million - $2.1 Million
2,004 New
2,004 $1.43 Billion
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $206,973 - $235,413
267 Added 59.73%
714 $627 Million
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $309,525 - $377,433
447 New
447 $368 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $352,945 - $383,195
500 New
500 $361 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $74.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.